Safety and Efficacy of TrenibotulinumtoxinE for Moderate-to-Severe Glabellar Lines: A Phase 2b, Double-Blind, Placebo-Controlled, Dose-Escalation Study
Clicks: 2
ID: 320905
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
2 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #42 of 72 articles by views in Aesthetic surgery journal
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Glabellar lines (GLs) are facial furrows that can become aesthetically displeasing because of aging and repetitive muscle contractions. OBJECTIVES: This dose-escalation study evaluated the safety and efficacy of trenibotulinumtoxinE for improving moderate-to-severe GL. METHODS: Adult participants were randomized 3:1 in each of 5 dosage cohorts to receive trenibotulinumtoxinE or placebo as 5 intramuscular injections into the glabellar complex on Day 1, with in-clinic visits through Day 42. The primary endpoint was improvement response (≥2-grade investigator-rated improvement in Facial Wrinkle Scale at maximum frown) assessed cumulatively through Day 7. Treatment satisfaction was assessed by responses of very satisfied or mostly satisfied on Facial Line Satisfaction Questionnaire Items 4 and 5 at Hour 24 and Day 7. RESULTS: The primary objectives were met: all dosage cohorts showed greater efficacy for trenibotulinumtoxinE than placebo, as measured cumulatively through Day 7 (all P < .01, unadjusted). Improvements were seen among Cohort 5 (highest dosage) as early as 8 h postintervention (16.1%, noncumulative responder rate); by Hour 24, the responder rate was 41.9%, with peak efficacy (93.3%) at Day 7 and a decline to 33.3% by Day 14 through Day 42. Responder rates increased with dose (Cohort 1, 40.6%; Cohort 5, 96.8%). At Day 7, more Cohort 5 participants than placebo participants were satisfied with natural look and effect of treatment. No serious adverse events were reported. No events were consistent with local diffusion or distant spread of toxin. CONCLUSIONS: TrenibotulinumtoxinE was efficacious and well tolerated across a range of doses in treating moderate-to-severe GL. LEVEL OF EVIDENCE: 1 (THERAPEUTIC): For image description, please refer to the figure legend and surrounding text.
| Reference Key |
openalex_W7168278011
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Edward Lain, Leslie Baumann, Suzanne Bruce, Janet DuBois, Rosalyn George, C William Hanke, Stuart Lessin, Mitchell F Brin, Amy Weitzenfeld, Chung-Yi C Chiang, Grace S Park-West, Sandhya Shimoga, Joan-En Chang-Lin |
| Journal | Aesthetic surgery journal |
| Year | 2026 |
| DOI |
10.1093/asj/sjag126
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.